The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Designed helical peptides inhibit an intramembrane protease.
Chittaranjan Das; Oksana Berezovska; Thekla S Diehl; Cedric Genet; Ilya Buldyrev; Jui-Yi Tsai; Bradley T Hyman; Michael S Wolfe (Profiled Author: Hyman, Bradley T)
Center for Neurologic Diseases, Harvard Medical School, Boston, Massachusetts 02115, USA.
Journal of the American Chemical Society 2003;125(39):11794-5.
gamma-Secretase cleaves the transmembrane domain of the amyloid precursor protein, a process implicated in the pathogenesis of Alzheimer's disease, and this enzyme is a founding member of an emerging class of intramembrane proteases. Modeling and mutagenesis suggest a helical conformation for the substrate transmembrane domain upon initial interaction with the protease. Moreover, biochemical evidence supports the presence of an initial docking site for substrate on gamma-secretase that is distinct from the active site, a property predicted to be generally true of intramembrane proteases. Here we show that short peptides designed to adopt a helical conformation in solution are inhibitors of gamma-secretase in both cells and enzyme preparations. Helical peptides with all d-amino acids are the most potent inhibitors and represent potential therapeutic leads. Subtle modifications that disrupt helicity also substantially reduce potency, suggesting that this conformation is critical for effective inhibition. Fluorescence lifetime imaging in intact cells demonstrates that helical peptides disrupt binding between substrate and protease, whereas an active site-directed inhibitor does not. These findings are consistent with helical peptides interacting with the initial substrate docking site of gamma-secretase, suggesting a general strategy for the development of potent and specific inhibitors of intramembrane proteases.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Golde, Todd E
10 April 2000 - 30 April 2009
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Total Funding: $ 2,532,291
TANZI, RUDOLPH EMILE
30 September 2012 - 31 August 2017
NATIONAL INSTITUTE ON AGING
Total Funding: $ 345,936
SELKOE, DENNIS J
1 September 1985 - 30 April 2017
NATIONAL INSTITUTE ON AGING
Total Funding: $ 2,223,247
N Chevallier; J Vizzavona; P Marambaud; C P Baur; M Spillantini; P Fulcrand; J Martinez; M Goedert; J P Vincent; F CheclerBrain research 1997;750(1-2):11-9.
C McLendon; T Xin; C Ziani-Cherif; M P Murphy; K A Findlay; P A Lewis; I Pinnix; K Sambamurti; R Wang; A Fauq; et al.FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2000;14(15):2383-6.
C L Moore; T S Diehl; D J Selkoe; M S WolfeAnnals of the New York Academy of Sciences 2000;920():197-205.
Appears in this Publication
Author of this Publication